Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells

Hoffmann, Sebastian; Rockenstein, Andreas; Ramaswamy, A.; Çelik, I.; Wunderlich, Annette; Lingelbach, Susanne; Hofbauer, Lorenz C.; Zielke, A.

doi:10.1016/j.mce.2006.10.009

Cited by 44 publications

(27 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Past and current concept of metastases initiating tumor cells highlights the importance of cell adhesion proteins, proteases, and angiogenesis. Retinoids and bexarotene have been shown to inhibit angiogenesis and metastasis in lung and thyroid cancer murine models (39,40). RA was shown to decrease secretion of VEGF in thyroid tumor cells in vitro (39).…”

Section: Before Treatmentmentioning

confidence: 99%

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Cras

Politis

Balitrand

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid cancer with loss of radioiodine uptake. The aim of this study was to improve the understanding of RA resistance and investigate the role of bexarotene in thyroid cancer cells.Experimental Design: A model of thyroid cancer cell lines with differential response to RA was used to evaluate the biological effects of retinoid and rexinoid and to correlate this with RA receptor levels. Subsequently, thyroid cancer patients were treated with 13-cis RA and bexarotene and response evaluated on radioiodine uptake reinduction on posttherapy scan and conventional imaging.Results: In thyroid cancer patients, 13-cis RA resistance can be bypassed in some tumors by bexarotene. A decreased tumor growth without differentiation was observed confirming our in vitro data. Indeed, we show that ligands of RARs or RXRs exert different effects in thyroid cancer cell lines through either differentiation or inhibition of cell growth and invasion. These effects are associated with restoration of RARb and RXRg levels and downregulation of NF-kB targets genes. We show that bexarotene inhibits the transactivation potential of NF-kB in an RXR-dependent manner through decreased promoter permissiveness without interfering with NF-kB nuclear translocation and binding to its responsive elements. Inhibition of transcription results from the release of p300 coactivator from NF-kB target gene promoters and subsequent histone deacetylation.Conclusion: This study highlights dual mechanisms by which retinoids and rexinoids may target cell tumorigenicity, not only via RARs and RXRs, as expected, but also via NF-kB pathway. Clin Cancer Res; 18(2); 442-53. Ó2011 AACR.

show abstract

Section: Before Treatmentmentioning

confidence: 99%

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Cras

Politis

Balitrand

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Recent studies with the RA isomer 13-cis-RA have shown that this drug can induce re-differentiation of thyroid carcinoma cell lines in vitro, as suggested by increased expression of some thyroid-specific proteins (9,10,20,21) and by the increase of cellular radioiodine uptake (22)(23)(24)(25). In several clinical studies, RA administration was able to re-induce iodine uptake in 20 to 50% of patients (12,16,26).…”

Section: Discussionmentioning

confidence: 99%

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma

Coelho

Vaisman

Buescu

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

“…1). Additionally, some oncogenic processes such as angiogenesis are inhibited by RA [8], and RA seems to directly inhibit tumor proliferation to some degree.…”

Section: Retinoic Acidsmentioning

confidence: 99%

Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

Paeng

Kang

Park

et al. 2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Thyroid cancer is one of the most rapidly increasing cancers in many countries. Although most thyroid cancers are differentiated cancers and easily treated with radioiodine (RI), a portion of differentiated and undifferentiated cancers is refractory not only to RI therapy, but also to radiotherapy and chemotherapy. Thus, various alternative therapies have been tested in RI-refractory thyroid cancers. These alternative therapies include two major categories: redifferentiation therapy and recent molecular target therapy. Several clinical trials have investigated these therapies. They demonstrated potential effects of the therapies, although the results have been somewhat limited so far. Thus, the future strategy for undifferentiated thyroid cancers will involve individualized, lesion-specific, and combined therapy. In this review, the basic mechanism of each redifferentiation and molecular target therapy is discussed, and results of recent clinical trials using these therapeutic agents are summarized.

show abstract

Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells

Cited by 44 publications

References 48 publications

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma

Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

Contact Info

Product

Resources

About